Tuesday's Key Wall Street Ratings: BofA Maintains Buy on Apple, BofA Downgrades Marvell
nashnova research
On November 3, multiple Wall Street firms reshuffled ratings — BofA cut Marvell from Buy to Neutral with a target slashed to $225, triggered by dilution fears over the all-stock Lumentum deal, while Apple, Nvidia and Palantir held their bullish calls.
Marvell got downgraded — what exactly happened?
BofA slashed Marvell's target from $400 to $225 and cut the rating from Buy to Neutral.
The trigger: Marvell announced an all-stock acquisition of Lumentum. This means → no cash changes hands; the company pays entirely by issuing new shares, diluting existing holders.
BofA warned the deal could create "prolonged stock-price overhang", compounded by a recent sector-wide valuation compression.
In plain terms = the acquisition itself isn't necessarily bad, but paying entirely in stock is like spending shareholders' equity — the market voted no first.
Apple, Nvidia, Palantir — why do they still get bullish calls?
BofA maintained Apple at Buy on three legs: strong capital returns, a path to becoming the edge-AI — running AI directly on devices like iPhones — ultimate winner, and option value in new products.
Bernstein reiterated Nvidia at Outperform with a one-line thesis: the data-center opportunity is massive.
Deutsche Bank reiterated Palantir at Buy, noting commercial and government growth are accelerating in tandem, with the latest quarter beating expectations across the board.
This reflects a market that still trusts the AI supply chain — the Marvell downgrade hasn't shaken conviction; capital is simply sorting out who has the highest growth certainty.
Which names were newly covered or upgraded?
Morgan Stanley initiated coverage on Pony AI at Overweight, calling it a leader in autonomous-driving mobility with rapid Robotaxi expansion in China.
Goldman Sachs upgraded SiriusXM from Neutral to Buy with a $37 target, citing rising spectrum option value and a bigger YouTube ad-partnership contribution post-2027.
J.P. Morgan upgraded Cloudflare from Neutral to Overweight — the stock's roughly 20% drop over the past month has narrowed its valuation premium, offering an entry point.
Barclays upgraded Bloom Energy to Overweight, noting accelerating capacity expansion and rising customer prepayments signal demand growth above prior expectations.
What other moves are worth watching?
Wedbush initiated coverage on Nano Nuclear Energy (NNE) at Outperform with an $18 target.
KeyBanc upgraded Howmet Aerospace to Overweight with a $237 target — an ~11% decline over six months provides relative value.
J.P. Morgan initiated coverage on TRex Bio (TRXB) at Overweight with a $20 target (December 2027 horizon).
Morgan Stanley reiterated EchoStar at Overweight, arguing a merger with SpaceX carries strategic logic — EchoStar holds low- and mid-band spectrum (~30 MHz), Boost Wireless (~$1–2 billion) and Dish DBS (~$7 billion), none of which are priced into the stock.
BMO reshuffled insurance brokers — who's up, who's down?
BMO upgraded Marsh & McLennan and AON from Market Perform to Outperform.
At the same time, it downgraded Arthur J. Gallagher to Market Perform.
This means → BMO sees the competitive landscape for large-employer clients favoring Marsh and AON, with Gallagher's edge in that segment relatively weaker.
What's the single most important takeaway from this rating wave?
The Marvell downgrade is the most substantive change in this cycle — all-stock dilution pressure plus sector valuation compression broke the prior bull case.
The key watch point going forward: whether Marvell's stock can absorb this overhang or slides further.
In plain terms = most other moves are either "it's fallen enough to buy" or "growth confirmed, keep holding." Only Marvell saw its fundamental thesis undermined.
市场有风险，内容仅供研究参考，不构成投资建议。